CG Oncology
NASDAQ · CGON·Irvine, CA·Mid-cap·Phase 3
Clinical-stage biotech developing cretostimogene grenadenorepvec, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Multiple Phase 3 trials including BOND-003 and PIVOT-006 underway.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| CG Oncology Investor Presentation | Corporate overview | April 15, 2026 | 28 |